Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 1 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

INDUSTRY 8 OTHER 4 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Radiotherapy 138 Cyclophosphamide 108 Cisplatin 103 Doxorubicin 99 Vincristine 76 Filgrastim 60 Etoposide 58 Paclitaxel 56 Carboplatin 53 Fluorouracil 51 Methotrexate 49 Dexamethasone 49 Cytarabine 43 Prednisone 42 Leucovorin 40 Granulocyte Colony-Stimulating Factor 34 Docetaxel 34 Radiation 31 Specimen Handling 30 Tamoxifen 27 Daunorubicin 27 Magnetic Resonance Spectroscopy 26 Calcium Dobesilate 26 Ifosfamide 25 Mercaptopurine 24 Gemcitabine 24 Platinum 22 Goserelin 22 1,2-diaminocyclohexaneplatinum II citrate 22 Chemotherapy, Adjuvant 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NETWORK × Trabectedin × Clear all

NCT02929394 2020-09-02

Trabectedin Maintenance Post 1st-line in STS

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡